BLTE

Belite Bio, Inc

$148.72

+$3.00 (2.06%)Oct 28 close

Healthcare Compare Technicals

1M 3M 6M 1Y 2Y

BLTESPY

Wall St. Highest PT $303.00 (+103.7%) Wall St. Avg PT $228.89 (+53.9%)

Underwater Drawdown %Max DD -29.1%Current -23.2%

Relative Strength vs SPY+44.6% vs SPYOutperforming

−$4.46 (2.91%)

−$17.21 (10.37%)

−$3.72 (2.44%)

−$5.78 (3.74%)

YTD

−$11.24 (7.03%)

+$55.70 (59.88%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar

Wall Street analyst consensus

Strong Buy

9 analysts · mean score 1.22

1 = Strong Buy · 5 = Sell

Wall Street consensus

Analyst price targets

Current price$148.72

Average target$228.89

+$80.17 (+53.9%) upsideaverage target vs current price

CurrentAverageMedian

Low$185.00

Median$228.89

High$303.00

12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$6.2B

P/E (next 12 months, estimated)67.8

52-week range$88.00 – $200.00

Dividend yieldNo dividend

Analyst consensusStrong Buy (9)

Average analyst price target$228.89 (+54%)

What they do

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.

Healthcare · Biotechnology

Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for BLTE yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth

Outside this model's universe or screens

Momentum Top 15

Outside this model's universe or screens

Momentum Blend

Not in the current book

New Highs Growth

Outside this model's universe or screens

SURVYR. Barbell Momentum & T-Bill Shield

Outside this model's universe or screens

SURVYR. Physical AI Grid & Power

Outside this model's universe or screens

SURVYR. Long Book

Not in the current book

Earnings & events

BLTE earningsNext report in 12 days

Next report · quarter Sep 2026

Mon Nov 9, 2026Time not confirmed

EPS consensus-$0.77

Revenue consensus–

Last 4 quarters · EPS vs estimate

Aug 13, 2026-$0.70est -$0.78+9.9%Above estimates

May 20, 2026-$0.68est -$0.64−5.8%Below estimates

Mar 2, 2026-$0.70est -$0.54−30.3%Below estimates

Nov 10, 2025-$0.65est -$0.49−32.6%Below estimates

In line = within 1% of the estimate.

EstimateActual (beat)Actual (miss)

News & catalysts

More news

No recent headlines.

Insider trades

Scholl Hendrik Peter